- 12/12/2016 9:18:00 AM
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, and Synthon Biopharmaceuticals B.V., an international biopharmaceutical company with highly focused development activities for new molecular entities in the therapeutic areas of oncology and autoimmune diseases, today announced they have entered a license and collaboration agreement for the development of MGC018, an antibody-drug conjugate (ADC) directed against solid tumors expressing B7-H3. This molecule is based on a MacroGenics proprietary B7-H3 antibody and Synthon’s proprietary duocarmycin-based, linker-drug technology.
- 5/18/2016 8:41:33 AM
Synthon Biopharmaceuticals (‘Synthon’) today announced the initiation of the second part of its ongoing Phase I clinical trial with the investigational anti-HER2 antibody-drug conjugate (ADC) SYD985. The second part will see 48 additional heavily pre-treated patients with HER2-positive breast cancer enrolled into the SYD985.001 trial. This marks an important next step in the development of SYD985, the frontrunner of Synthon’s duocarmycin-based ADC platform.
- 4/12/2016 9:00:10 AM
Synthon today announced that it has successfully concluded the decentralized procedures for glatiramer acetate, a therapeutically equivalent version of the originator medicine Copaxone®* for the treatment of relapsing remitting multiple sclerosis (RRMS). All 29 member states included in the decentralized procedures supported approval of the product.
- 9/28/2015 10:55:59 AM
Efficacy observed in breast cancer patients refractory to trastuzumab and trastuzumab-emtansine treatments
- 8/3/2015 2:11:09 PM
Synthon’s glatiramer acetate, a potential generic version of Copaxone® for the treatment of relapsing remitting multiple sclerosis is currently being reviewed by the U.S. Food and Drug Administration
- 4/28/2015 8:59:00 AM
Synthon announces that data from the open-label extension of the Phase III GATE study of the Company’s generic glatiramer acetate in patients with relapsing remitting multiple sclerosis (RRMS) demonstrate that efficacy, safety and tolerability were maintained over the entire two-year study period. The data further support the safety of switching from Copaxone® to Synthon’s glatiramer acetate.